Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice

With the increasing obesity prevalence, the rates of obesity-related diseases, including type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases, have increased dramatically. Dapagliflozin, one of the sodium glucose cotransporter inhibitors, not only exerts hypoglycae...

Full description

Saved in:
Bibliographic Details
Published in:Adipocyte 2021-01, Vol.10 (1), p.446-455
Main Authors: Han, Tuo, Fan, Yajie, Gao, Jie, Fatima, Mahreen, Zhang, Yali, Ding, Yiming, Bai, Liang, Wang, Congxia
Format: Article
Language:English
Subjects:
Adiposity
Animals
Benzhydryl Compounds
browning
Dapagliflozin
Diabetes Mellitus, Type 2 - drug therapy
Diet, High-Fat - adverse effects
Glucosides
hepatic steatosis
high-fat diet
Insulin Resistance
Mice
Mice, Inbred C57BL
Mice, Obese
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic Fatty Liver Disease - etiology
Obesity - drug therapy
Research Paper
Sodium-Glucose Transporter 2 Inhibitors - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With the increasing obesity prevalence, the rates of obesity-related diseases, including type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases, have increased dramatically. Dapagliflozin, one of the sodium glucose cotransporter inhibitors, not only exerts hypoglycaemic effects through increasing urinary glucose excretion but alsoreprograms the metabolic system, leading to benefits in metabolic and cardiovascular diseases. In this study, pre-established obese mice on a high-fat diet were given dapagliflozin by gavage for fourweeks. It showed that dapagliflozin can enhance fat utilization and browning of adipose tissue and improve local oxidative stress, thus inhibiting fat accumulation and hepatic steatosis without disturbance in body weight or plasma glycolipid level. Overall, our study highlights the potential clinical application of SGLT2 inhibition in the prevention of obesity and related metabolic diseases, such as insulin resistance, NAFLD, and diabetes.
ISSN:2162-3945
2162-397X
DOI:10.1080/21623945.2021.1979277